Xeris Biopharma Holdings (XERS) Prepaid Assets (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Prepaid Assets of $9.4 million for Q1 2026, down 1.52% on a QoQ basis from $9.5 million in Q4 2025, and up 55.83% year-over-year from $6.0 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Prepaid Assets (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Prepaid Assets history runs 7 years deep, the most recent figure standing at $9.4 million for Q1 2026.
- Quarterly Prepaid Assets rose 55.83% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 55.83% YoY) and the FY2025 annual result came in at $9.5 million, up 28.14% from the prior year.
- Prepaid Assets was $9.4 million for Q1 2026 at Xeris Biopharma Holdings, down from $9.5 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $11.2 million in Q3 2025 and bottomed at $5.1 million in Q1 2022.
- A 5-year average of $7.8 million and a median of $7.6 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 119.07% — and 2023, when it slumped 37.78%.
- Xeris Biopharma Holdings' Prepaid Assets stood at $9.3 million in 2022, then tumbled by 37.78% to $5.8 million in 2023, then gained by 28.95% to $7.5 million in 2024, then grew by 28.14% to $9.5 million in 2025, then fell by 1.52% to $9.4 million in 2026.
- Business Quant data shows XERS's Prepaid Assets at $9.4 million in Q1 2026, $9.5 million in Q4 2025, and $11.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.40 Mn |
| Dec 31, 2025 | 9.55 Mn |
| Sep 30, 2025 | 11.21 Mn |
| Jun 30, 2025 | 5.96 Mn |
| Mar 31, 2025 | 6.03 Mn |
| Dec 31, 2024 | 7.45 Mn |
| Sep 30, 2024 | 7.14 Mn |
| Jun 30, 2024 | 7.36 Mn |
| Mar 31, 2024 | 7.64 Mn |
| Dec 31, 2023 | 5.78 Mn |
| Sep 30, 2023 | 7.97 Mn |
| Jun 30, 2023 | 8.31 Mn |
| Mar 31, 2023 | 10.51 Mn |
| Dec 31, 2022 | 9.29 Mn |
| Sep 30, 2022 | 7.85 Mn |
| Jun 30, 2022 | 6.01 Mn |
| Mar 31, 2022 | 5.15 Mn |
| Dec 31, 2021 | 4.59 Mn |
| Sep 30, 2021 | 3.58 Mn |
| Dec 31, 2020 | 3.20 Mn |